Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP.
Aged
Biomarkers
/ analysis
Bronchoalveolar Lavage Fluid
/ chemistry
Calgranulin B
/ analysis
Case-Control Studies
Cell Count
Humans
Idiopathic Interstitial Pneumonias
/ metabolism
Idiopathic Pulmonary Fibrosis
/ metabolism
Middle Aged
Mucin-1
/ analysis
Neutrophils
/ cytology
Oxygen Consumption
Severity of Illness Index
KL-6
biomarkers
bronchoalveolar lavage
calgranulin B
idiopathic pulmonary fibrosis
non-specific interstitial pneumonia
Journal
Inflammation
ISSN: 1573-2576
Titre abrégé: Inflammation
Pays: United States
ID NLM: 7600105
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pubmed:
27
1
2019
medline:
3
8
2019
entrez:
26
1
2019
Statut:
ppublish
Résumé
Idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) are the most frequent idiopathic interstitial pneumonias. The aim of this study was to evaluate concentrations of calgranulin B and Krebs von den Lungen 6 (KL-6) in bronchoalveolar lavage (BAL) fluid of patients with IPF and idiopathic NSIP (i-NSIP) with fibrotic pattern. Thirty patients with IPF (68.73 ± 8.63 years), 30 with i-NSIP (68.33 ± 7.45 years), and healthy controls were included in the study. Calgranulin B and KL-6 both proved to be significantly higher in BAL of IPF and i-NSIP patients than in healthy controls (p < 0.05). Calgranulin B showed several significant correlations with functional parameters (oxygen demand at rest, 6-min walking test (6MWT), and PFTs); KL-6 was correlated with oxygen demand at rest and during 6MWT. Patients with higher concentrations of both biomarkers (> 75th percentile) had more advanced disease with lower values of FEV1%, FVC%, RV%, TLC%, DLCO% of predicted, distance walked in 6MWT, and BAL neutrophil percentage. Calgranulin B and KL-6 in BAL proved to be reliable biomarkers of IPF and i-NSIP and to have prognostic meaning, discriminating severe and advanced patients. The combination of the two biomarkers can facilitate the stratification of severity.
Identifiants
pubmed: 30680696
doi: 10.1007/s10753-018-00955-2
pii: 10.1007/s10753-018-00955-2
doi:
Substances chimiques
Biomarkers
0
Calgranulin B
0
MUC1 protein, human
0
Mucin-1
0
Types de publication
Journal Article
Langues
eng
Pagination
463-470Commentaires et corrections
Type : CommentIn
Références
Eur Respir J. 2005 Jul;26(1):153-61
pubmed: 15994402
Respirology. 2006 Mar;11(2):164-8
pubmed: 16548901
Inflammation. 2008 Oct;31(5):351-4
pubmed: 18784990
Respir Med. 2010 Jan;104(1):127-33
pubmed: 19811899
Inflammation. 2011 Apr;34(2):85-91
pubmed: 20422274
Clin Exp Immunol. 2010 Aug;161(2):342-7
pubmed: 20550547
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Sarcoidosis Vasc Diffuse Lung Dis. 2011 Jul;28(1):27-33
pubmed: 21796888
Respir Med. 2012 Apr;106(4):571-80
pubmed: 22209187
Am J Respir Crit Care Med. 2012 May 1;185(9):1004-14
pubmed: 22550210
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Respir Med. 2014 Jul;108(7):1031-9
pubmed: 24835074
Eur Respir J. 2014 Dec;44(6):1428-46
pubmed: 25359355
Eur Respir J. 2015 Mar;45(3):746-55
pubmed: 25537566
Curr Top Med Chem. 2016;16(14):1587-98
pubmed: 26420365
Zhonghua Jie He He Hu Xi Za Zhi. 2016 Feb;39(2):93-7
pubmed: 26879611
Oncogene. 2016 Nov 3;35(44):5735-5745
pubmed: 27086923
Orphanet J Rare Dis. 2016 Apr 23;11:48
pubmed: 27108412
Dis Markers. 2016;2016:4759040
pubmed: 27293304
Respir Investig. 2017 Jan;55(1):16-23
pubmed: 28012488
Am J Surg Pathol. 1994 Feb;18(2):136-47
pubmed: 8291652